Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott soon after entering into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE (FRA:EVT) – a leading European drug discovery and development company. The agreement was made for EVT801 – a small molecule, first-in class oncology drug candidate, for which Kazia expects to launch a phase-I clinical trial in 2021.
Kazia Therapeutics bolsters pipeline with new first-in-class oncology drug candidate
